In a 4-week RCT involving patients with obesity and T2D, infusion of acombination of GLP-1, OXM, and Peptide YY (GOP) resulted in significantimprovements in glycemic control and moderate weight loss compared to placebo.GOP therapy also reduced fructosamine levels and improved postprandial glucosetolerance. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.